nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

10.08.2022 | Letter to the Editor

The era of prostate-specific membrane antigen (PSMA)–based theranostics for hepatocellular carcinoma is upcoming: are we ready for it?

verfasst von: Luca Filippi, Arthur J. Braat, Orazio Schillaci

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 12/2022

Einloggen, um Zugang zu erhalten

Excerpt

Dear Sir, …

Lu Q, Long Y, Fan K, Shen Z, Gai Y, Liu Q, et al. PET imaging of hepatocellular carcinoma by targeting tumor-associated endothelium using [68Ga]Ga-PSMA-617. Eur J Nucl Med Mol Imaging. 2022. https://doi.org/10.1007/s00259-022-05884-9.CrossRefPubMedPubMedCentral

Zhang C, Cheng Y, Zhang S, Fan J, Gao Q. Changing epidemiology of hepatocellular carcinoma in Asia. Liver Int. 2022. https://doi.org/10.1111/liv.15251.CrossRefPubMed

Chen J, Xiong P, Nie M, Pan Y, Wang J, Hu D, et al. The combination treatment strategy of lenvatinib for hepatocellular carcinoma: a real-world study. J Cancer Res Clin Oncol. 2022. https://doi.org/10.1007/s00432-022-04082-2.CrossRefPubMedPubMedCentral

Abdelrahim M, Esmail A, Umoru G, Westhart K, Abudayyeh A, Saharia A, et al. Immunotherapy as a neoadjuvant therapy for a patient with hepatocellular carcinoma in the pretransplant setting: a case report. Curr Oncol. 2022;29:4267–73.CrossRef

Dondi F, Albano D, Cerudelli E, Gazzilli M, Giubbini R, Treglia G, et al. Radiolabelled PSMA PET/CT or PET/MRI in hepatocellular carcinoma (HCC): a systematic review. Clin Transl Imaging. 2020;8:461–7.CrossRef

Filippi L, Braat AJ. Theragnostics in primary and secondary liver tumors: the need for a personalized approach. Q J Nucl Med Mol Imaging. 2021;65:353–70.PubMed

Kesler M, Levine C, Hershkovitz D, Mishani E, Menachem Y, Lerman H, et al. ⁶⁸ Ga-labeled prostate-specific membrane antigen is a novel PET/CT tracer for imaging of hepatocellular carcinoma: a prospective pilot study. J Nucl Med. 2019;60:185–91.CrossRef

Talbot J-N, Michaud L, Grange J-D, Rosmorduc O, Balogova S. Use of choline PET for studying hepatocellular carcinoma. Clin Transl Imaging. 2014;2:103–13.CrossRef

Hirmas N, Leyh C, Sraieb M, Barbato F, Schaarschmidt BM, Umutlu L, et al. ⁶⁸ Ga-PSMA-11 PET/CT improves tumor detection and impacts management in patients with hepatocellular carcinoma. J Nucl Med. 2021;62:1235–41.CrossRef

Titel: The era of prostate-specific membrane antigen (PSMA)–based theranostics for hepatocellular carcinoma is upcoming: are we ready for it?
verfasst von: Luca Filippi
Arthur J. Braat
Orazio Schillaci
Publikationsdatum: 10.08.2022
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 12/2022
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-022-05928-0

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2022

Increased TSPO PET signal after radiochemotherapy in IDH-wildtype glioma—indicator for treatment-induced immune activation?

Application of machine learning to pretherapeutically estimate dosimetry in men with advanced prostate cancer treated with 177Lu-PSMA I&T therapy

PET imaging of hepatocellular carcinoma by targeting tumor-associated endothelium using [68Ga]Ga-PSMA-617

Predicting response of micrometastases with MIRDcell V3: proof of principle with 225Ac-DOTA encapsulating liposomes that produce different activity distributions in tumor spheroids

Repair of α-particle-induced DNA damage in peripheral blood mononuclear cells after internal ex vivo irradiation with 223Ra

[64Cu]Cu-ATSM: an emerging theranostic agent for cancer and neuroinflammation